Mayo Clinic develops a tool to forecast Alzheimer’s risk prior to symptom onset

Mayo Clinic Researchers Estimate Alzheimer’s Risk Early

A team of scientists at the Mayo Clinic has developed a new method to evaluate an individual’s risk of experiencing memory and cognitive issues that often signal the onset of Alzheimer’s disease, potentially altering future detection and treatment approaches.

The findings, shared in The Lancet Neurology, are based on extensive data collected from the Mayo Clinic Aging Study, which has been following thousands of participants over several years.

Dr. Clifford Jack Jr., a radiologist at the Mayo Clinic in Rochester, Minnesota, led the research, examining brain scans, genetics, and medical histories of over 5,800 adults. From this data, the team crafted a predictive model assessing both a person’s decade-long and lifetime likelihood of developing cognitive decline.

Before the more evident signs of memory loss or confusion arise, two key proteins, amyloid and tau, accumulate in the brain. Amyloid creates sticky plaques, while tau forms tangles in brain cells. Together, these proteins disrupt neuron communication, leading to the cognitive impairments characteristic of Alzheimer’s.

Using specialized brain imaging to gauge amyloid buildup, researchers evaluated the “biological severity” of Alzheimer’s in cognitively healthy individuals. Results were represented on a scale from 0 to 100, indicating that lower scores signify minimal amyloid presence while higher scores suggest significant accumulation.

Ronald Petersen, MD, a neurologist and co-author of the study, indicated that this type of risk assessment might assist patients and doctors in deciding when to initiate treatment or consider lifestyle modifications that could postpone symptom onset. He compared it to cholesterol levels in predicting heart attack risks.

The study considered various factors, including age, gender, and the presence of the APOEε4 gene, which is linked to a greater risk of Alzheimer’s. Advanced statistical methods were employed to forecast each participant’s chances of developing mild cognitive impairment (MCI) and subsequently, dementia.

Higher levels of amyloid were associated with a heightened lifetime and 10-year risk of memory issues. A 75-year-old woman in the research carried a genetic mutation and exhibited considerable amyloid buildup, resulting in over an 80% lifetime probability of developing MCI, which represents a critical transition phase between typical aging and dementia.

Women were found to have a greater lifetime risk than men, and those carrying the gene faced higher odds of cognitive decline than those who did not.

Despite the promising findings, the researchers acknowledged several limitations. The study predominantly involved older white adults from a single region, meaning the results might not be applicable across diverse populations. Moreover, it utilized costly brain scans that aren’t widely available and didn’t factor in lifestyle choices or health habits that could influence memory health.

For the moment, this new tool remains a research project. However, Mayo Clinic scientists believe it’s a significant advancement towards tailored Alzheimer’s prevention strategies. Future iterations may incorporate simple blood tests for amyloid and other relevant biomarkers, simplifying risk assessments.